It is therefore highly likely that anti-ARHGAP26 autoantibodies will eventually be found to correlate with various clinical conditions associated with affective disorders, cerebral ischemia, or cerebellar ataxia, but further investigation is needed to provide evidence of brain inflammation and neuronal damage, suggesting the clinical relevance of these autoantibodies. This evidence concerns the gene ARHGAP26 and Cerebral ischemia.